What is the name of the vaginal estrogen cream to prescribe and its dosing regimen for a post‑menopausal woman with vaginal atrophy?

Vaginal Estrogen Cream for Postmenopausal Vaginal Atrophy

For postmenopausal women with vaginal atrophy, prescribe conjugated estrogens (CEE) vaginal cream 0.3 mg applied intravaginally daily or twice weekly, or estradiol vaginal cream 2-4 g (containing estradiol) applied daily for 1-2 weeks followed by 1 g one to three times weekly. 1

Available Vaginal Estrogen Cream Formulations

The Endocrine Society guidelines categorize vaginal estrogen preparations into low, intermediate, and systemic doses, with the recommendation to use the lowest effective dose to minimize systemic absorption 1.

Intermediate-Dose Creams (Preferred Starting Point)

Conjugated Estrogens (CEE) Cream 0.3 mg:

• Dosing: Apply 0.3 mg intravaginally either daily OR twice weekly 1
• Efficacy: Improves vaginal atrophy symptoms by 12 weeks, sustained through 52 weeks 1
• Evidence: RCT data demonstrates no endometrial effects with this regimen 1
• Advantage: Provides dosing flexibility and allows treatment from introitus to vaginal apex with emollient effect 1

Estradiol Vaginal Cream:

• Dosing: 2-4 g cream applied daily for 1-2 weeks, then maintenance of 1 g one to three times weekly 1
• Note: This is FDA-approved dosing, though the guidelines note limited RCT data for this specific regimen 1

Systemic-Dose Creams (Use with Caution)

CEE 0.625-2.5 mg vaginal cream:

• Applied daily
• Caution: Results in systemic effects (LH/FSH suppression) 1
• The guidelines note insufficient data to recommend this approach due to systemic absorption 1

Clinical Algorithm for Prescribing

Step 1: Confirm diagnosis

• Vaginal pH >5
• ≤5% superficial cells on vaginal smear
• Moderate-to-severe symptoms (dryness, dyspareunia, irritation, burning) 2

Step 2: Choose formulation based on patient factors

• CEE cream 0.3 mg is preferred when you want:

  • Proven 52-week safety data without endometrial effects 1
  • Flexibility between daily or twice-weekly dosing 1
  • Coverage from introitus to apex 1

• Estradiol cream when patient prefers:

  • Standard FDA-approved regimen
  • Initial intensive therapy followed by maintenance 1

Step 3: Initiate therapy

• Start with chosen regimen
• Expect symptom improvement within 2-3 weeks 1
• Objective improvements continue through 12 weeks and maintain to 1 year 1

Important Clinical Considerations

Systemic Absorption:

• Low-dose vaginal estrogen maintains serum estradiol within normal postmenopausal range 1
• During initial therapy, vaginal atrophy may enhance systemic absorption, but this decreases once epithelium is restored after several weeks 1
• Research confirms CEE 0.3 mg cream shows no significant systemic absorption 3

Progestogen Use:

• Do NOT add progestogen with low-dose vaginal estrogen 1
• No need for endometrial protection with these doses 1

Safety Profile:

• No increased cardiovascular disease or venous thromboembolism risk reported 1
• No endometrial hyperplasia in 52-week studies of low-dose preparations 1, 3
• Side effects: vulvovaginal candidiasis, potential partner transfer, residue on undergarments 1

Critical Pitfall:

• If patient reports postmenopausal bleeding or spotting while on vaginal estrogen, immediately evaluate for endometrial pathology 1

Alternative Formulations (Non-Cream)

While you asked specifically about creams, be aware that vaginal estradiol 10-µg tablets (daily for 2 weeks, then twice weekly) are the most studied low-dose option with excellent efficacy and safety data through 52 weeks 1. The 2025 AUA/SUFU/AUGS guidelines strongly recommend local low-dose vaginal estrogen as first-line therapy, with route of administration individualized based on patient preference and ability to use consistently 4.